Rachel M Godfred, MD | |
22 Bramhall St, Portland, ME 04102-3134 | |
(207) 662-0111 | |
Not Available |
Full Name | Rachel M Godfred |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 22 Bramhall St, Portland, Maine |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1346877826 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | MD23915 (Maine) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Entity Name | Mainehealth |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when treated with E. coli asparaginase, a key chemotherapy drug for this type of leukemia.
The four out of ten women who use antibiotics during pregnancy can breathe easy, as a comprehensive new study shows that the two most often prescribed drugs have no adverse outcome on the child's physical development.
As if borrowing from a scene in a science fiction movie, researchers at Kyoto University have successfully developed a kind of tractor beam that can be used to manipulate the network of the molecules. In a paper soon to be published in Physical Review Letters, the team has demonstrated a technique using terahertz pulses that could have broad applications in the chemical and pharmaceutical industries.
A team of researchers from Indiana University and Memorial Sloan Kettering Cancer Center have been awarded a $4.1 million National Cancer Institute "Cancer Moonshot" grant to develop immunotherapy treatments for cancer in children and adolescents, especially those with leukemia.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Rachel M Godfred, MD 2500 81st Ave Se Apt 303, Mercer Island, WA 98040-2240 Ph: (206) 920-5480 | Rachel M Godfred, MD 22 Bramhall St, Portland, ME 04102-3134 Ph: (207) 662-0111 |
News Archive
One of the causes of resistance to cancer treatment in children is now beginning to be elucidated. Acute lymphoblastic leukemia patients with a particular form of the ATF5 gene are at higher risk of having a relapse when treated with E. coli asparaginase, a key chemotherapy drug for this type of leukemia.
The four out of ten women who use antibiotics during pregnancy can breathe easy, as a comprehensive new study shows that the two most often prescribed drugs have no adverse outcome on the child's physical development.
As if borrowing from a scene in a science fiction movie, researchers at Kyoto University have successfully developed a kind of tractor beam that can be used to manipulate the network of the molecules. In a paper soon to be published in Physical Review Letters, the team has demonstrated a technique using terahertz pulses that could have broad applications in the chemical and pharmaceutical industries.
A team of researchers from Indiana University and Memorial Sloan Kettering Cancer Center have been awarded a $4.1 million National Cancer Institute "Cancer Moonshot" grant to develop immunotherapy treatments for cancer in children and adolescents, especially those with leukemia.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease.
› Verified 7 days ago